Author Details

Poddubnaya, Irina V.

Issue Section Title File
Vol 21, No 4 (2019) CLINICAL ONCOLOGY The role of second generation Bruton tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Resolution PDF
(Rus)
Vol 22, No 1 (2020) CLINICAL ONCOLOGY Solitary (extramedullary) plasmocytoma. Clinical recommendations PDF
(Rus)
Vol 22, No 1 (2020) CLINICAL ONCOLOGY ELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution PDF
(Rus)
Vol 22, No 1 (2020) CLINICAL ONCOLOGY Modern view on the issues of diagnosis and verification of axillary lymph nodes involvement in early breast cancer PDF
(Rus)
Vol 22, No 2 (2020) Conference Proceedings Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic PDF
(Rus)
Vol 22, No 2 (2020) Original Article Maintenance oncohematological patients and new coronavirus infection: experience of the City Clinical Hospital №52 PDF
(Rus)
Vol 22, No 2 (2020) Conference Proceedings New opportunities of systemic therapy of CD30-positive primary cutaneous T-cell lymphomas PDF
(Rus)
Vol 22, No 2 (2020) Review Accompanying therapy in oncohematological patients with secondary immunodeficiency PDF
(Rus)
Vol 22, No 2 (2020) Best Practice Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience PDF
(Rus)
PDF
(Eng)
Vol 22, No 2 (2020) Original Article First-line therapy of indolent non-Hodgkin’s lymphoma in routine clinical practice PDF
(Rus)
Vol 22, No 4 (2020) CLINICAL ONCOLOGY Multiple myeloma PDF
(Rus)
Vol 22, No 4 (2020) CLINICAL ONCOLOGY The virtual forum on the diagnosis and treatment of PIK3CA-mutated metastatic breast cancer. October 16th, 2020. Event review PDF
(Rus)
Vol 22, No 4 (2020) CLINICAL ONCOLOGY Interim results of a multicenter retrospective-prospective observational post-marketing study of Extimia® BIOCAD (INN: empegfilgrastim) to evaluate safety and efficacy in patients with lymphoproliferative diseases receiving cytotoxic therapy PDF
(Rus)
Vol 23, No 1 (2021) CLINICAL ONCOLOGY Modern approaches in the first line treatment of CD30-positive peripheral T-cell lymphomas PDF
(Rus)
Vol 23, No 2 (2021) CLINICAL ONCOLOGY Biological features of ductal carcinoma in situ: clinical role and basis for treatment individualization PDF
(Rus)
Vol 23, No 3 (2021) CLINICAL ONCOLOGY Extrapulmonary small cell carcinoma. Literature review PDF
(Rus)
Vol 23, No 4 (2021) CLINICAL ONCOLOGY Features of response to modern neoadjuvant chemotherapy with dual anti-HER2 blockade (trastuzumab and pertuzumab) in the patients with HER2-positive breast cancer stage II–III PDF
(Rus)
Vol 24, No 1 (2022) CLINICAL ONCOLOGY Immuno-morphological characteristics of bone marrow in patients with ovarian cancer PDF
(Rus)
Vol 24, No 1 (2022) CLINICAL ONCOLOGY Therapy of lymphoproliferative diseases in the era of COVID-19: challenges and solutions PDF
(Rus)
Vol 24, No 1 (2022) CLINICAL ONCOLOGY From the editor-in-chief of the journal "Modern Oncology" Academician of the Russian Academy of Sciences I.V. Poddubnaya PDF
(Rus)
Vol 24, No 1 (2022) CLINICAL ONCOLOGY Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases who receive cytotoxic therapy: results of LEGERITY, the second interim analysis of multicenter retrospective-and-prospective observational post-marketing study PDF
(Rus)
Vol 24, No 3 (2022) CLINICAL ONCOLOGY Analysis of the complications of endocrine therapy with tamoxifen in breast cancer: clinical and pharmacogenetic aspects. Prospective pharmacogenetic cohort study PDF
(Rus)
Vol 24, No 2 (2022) CLINICAL ONCOLOGY Risk of discrimination against Russian citizens in providing medical care abroad as a health care trend PDF
(Rus)
Vol 24, No 3 (2022) CLINICAL ONCOLOGY The analysis of the relationship between transferrin receptor 1 (TfR1) and clinical, morphological and immunophenotypic characteristics of breast cancer: retrospective cohort study PDF
(Rus)
Vol 24, No 3 (2022) CLINICAL ONCOLOGY Genetic markers associated with resistance to radioiodine therapy in thyroid cancer patients: Prospective cohort study PDF
(Rus)
Vol 25, No 1 (2023) CLINICAL ONCOLOGY Clinical factors of the risk of hyperplastic endometry processes on tamoxifen therapy with breast cancer: Retrospective population study PDF
(Rus)
Vol 25, No 2 (2023) CLINICAL ONCOLOGY Interrelation of HLA-I and class II major histocompatibility complex molecules with clinical and morphological signs of breast cancer: A retrospective cohort study PDF
(Rus)
Vol 25, No 2 (2023) CLINICAL ONCOLOGY Heterogeneous diffuse large B-cell lymphoma: accurate diagnosis as a key to successful therapy. A review PDF
(Rus)
Vol 25, No 2 (2023) CLINICAL ONCOLOGY Challenges and perspectives of first-line therapy in patients with diffuse B-cell lymphoma: A review PDF
(Rus)
Vol 25, No 3 (2023) CLINICAL ONCOLOGY Diffuse large B-cell lymphoma: strokes to the epidemiological portrait. A review PDF
(Rus)
Vol 25, No 3 (2023) CLINICAL ONCOLOGY An interdisciplinary approach to the management of oncohematological patients with immunodeficiency: clinical cases. A review PDF
(Rus)
Vol 25, No 3 (2023) ИСТОРИЯ МЕДИЦИНЫ Memorial lecture to the 100th anniversary of the birth of Professor Yu.I. Lorie PDF
(Rus)
Vol 25, No 4 (2023) CLINICAL ONCOLOGY Can bispecific antibodies change the paradigm and goals of therapy for patients with relapsed non-Hodgkin lymphomas? PDF
(Rus)
Vol 25, No 4 (2023) CLINICAL ONCOLOGY Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases receiving cytotoxic therapy: results of LEGERITY, a multicenter retrospective-and-prospective observational post-marketing study PDF
(Rus)

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies